Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing

American Journal of Clinical Pathology

Volumn 144, Issue 5, 2015, Pages 713-721

  Roy Chowdhuri, Sinchita ^a   De Melo Gagliato, Debora ^a   Routbort, Mark J ^a   Patel, Keyur P ^a   Singh, Rajesh R ^a   Broaddus, Russell ^a   Lazar, Alexander J ^a   Sahin, Aysegul ^a   Alvarez, Ricardo H ^a   Moulder, Stacy ^a   Wheler, Jennifer J ^a   Janku, Filip ^a   Gonzalez Angulo, Ana M ^a   Chavez MacGregor, Mariana ^a   Valero, Vicente ^a   Ueno, Naoto T ^a   Mills, Gordon ^a   Mendelsohn, John ^a   Yao, Hui ^a   Aldape, Kenneth ^a   Luthra, Rajyalakshmi ^a   Meric Bernstam, Funda ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma; ER positive; Mutational profiling; Next generation sequencing; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN P53; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; MUTATION RATE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84947969268     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPWDEQYCYC92JQ     Document Type: Article

References (27)

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
2. American Cancer Society. Cancer facts & figures 2014. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed June 2014.
3. Kittaneh M, Montero AJ, Gluck S. Molecular profiling for breast cancer: a comprehensive review. Biomarkers Cancer. 2013; 5: 61-70.
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
5. Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005; 11: 278-280.
6. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5: 341-354.
7. Banin Hirata BK, Oda JM, Losi Guembarovski R, et al. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014; 2014: 513158.
8. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013; 3: 250.
9. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26: 1275-1281.
10. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009; 20: 1953-1958.
11. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012; 30: 593-599.
12. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011; 10: 1093-1101.
13. Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011; 17: 667-677.
14. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 2014; 13: 1382-1389.
15. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15: 607-622.
16. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010; 134: 907-922.
17. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014; 138: 241-256.
18. Kanagal-Shamanna R, Portier BP, Singh RR, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014; 27: 314-327.
19. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011; 475: 348-352.
20. Mouridsen HT, Rose C, Brodie AH, et al. Challenges in the endocrine management of breast cancer. Breast. 2003; 12(SUPPL. 2):S2-S19.
21. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608: 1-22.
22. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434.
23. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121: 2750-2767.
24. Mayer IA, Abramson VG, Lehmann BD, et al. New strategies for triple-negative breast cancer - deciphering the heterogeneity. Clin Cancer Res. 2014; 20: 782-790.
25. Santarpia L, Qi Y, Stemke-Hale K, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012; 134: 333-343.
26. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-404.
27. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: p11.